title: Memory Antitumor T-Cells Resist Inhibition by Immune Suppressor Cells.
abstract: Cancer immune therapy is difficult partly because several classes of suppressor cells, including regulatory T-cells and macrophage-derived suppressor cells, inhibit the antitumor T-cell response. We used treatment studies of implanted tumors in mice to demonstrate that the same inhibitory cells that abrogated an acute therapeutic T-cell response to established tumor did not inhibit the therapeutic response produced by memory T-cells. Generating antitumor memory T-cells may be a highly potent strategy against cancer with late developing metastases.
authors.affiliation: Department of Pediatrics, Microbiology, University of Pittsburgh School of Medicine, Pittsburgh, PA, U.S.A.
authors.forename: Yanhua
authors.initials: Y
authors.lastname: Gao
authors.affiliation: Department of Molecular Genetics, University of Pittsburgh School of Medicine, Pittsburgh, PA, U.S.A.
authors.forename: Patricia
authors.initials: P
authors.lastname: Whitaker-Dowling
authors.affiliation: Department of Pediatrics, Microbiology, University of Pittsburgh School of Medicine, Pittsburgh, PA, U.S.A. Department of Neurology, University of Pittsburgh School of Medicine, Pittsburgh, PA, U.S.A. Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, U.S.A. ira.bergman@chp.edu.
authors.forename: Ira
authors.initials: I
authors.lastname: Bergman
mesh_terms: D000818:Animals; D003520:Cyclophosphamide / Q000494:pharmacology; D005260:Female; D006801:Humans; D007156:Immunologic Memory / Q000187:drug effects; D007167:Immunotherapy; D008807:Mice, Inbred BALB C; D009369:Neoplasms / Q000276:immunology* / Q000473:pathology; D011995:Recombination, Genetic / Q000235:genetics; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology* / Q000473:pathology; D014721:Vesicular stomatitis Indiana virus / Q000187:drug effects; D014779:Virus Replication / Q000187:drug effects
chemical_list: D003520:Cyclophosphamide
keywords: Memory T-cells; cyclophosphamide; immunotherapy; vesicular stomatitis virus